Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Achieve Life Sciences announced the completion of the follow-up phase for the ORCA-2 Phase 3 trial, which evaluated the effectiveness of cytisinicline for smoking cessation. The trial involved 810 participants across 17 clinical sites in the U.S. and is part of Achieve's ongoing commitment to combat nicotine addiction. Topline results are expected in Q2 2022, with plans to initiate the ORCA-3 and ORCA-V1 trials later in the year. Cytisinicline is an investigational treatment that targets nicotine withdrawal symptoms and has yet to receive FDA approval.
- Completion of the ORCA-2 trial follow-up phase marks a significant milestone.
- Topline results for the ORCA-2 trial are expected in Q2 2022, indicating progress in cytisinicline development.
- Plans for ORCA-3 and ORCA-V1 trials suggest ongoing commitment to addressing nicotine addiction.
- Cytisinicline has not received FDA approval, posing uncertainty for future commercialization.
- Potential risks and uncertainties related to achieving expected benefits and securing additional financing for development.
Topline ORCA-2 Results Expected in Q2 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021.
The ORCA-2 trial is the first Phase 3 trial in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily (TID) for either 6 or 12 weeks, compared with placebo. Subjects in the trial received standard behavioral support during treatment and while completing follow-up assessments through 24 weeks post randomization. ORCA-2 randomized 810 subjects across 17 clinical trial sites in the United States. Topline data regarding the primary results are expected in the second quarter of 2022.
"Completion of the follow-up phase in the ORCA-2 trial represents another significant milestone in our cytisinicline development pipeline,” commented Dr. Cindy Jacobs, President and Chief Medical Officer of Achieve. “We look forward to sharing topline data from the study in the coming months and continuing to move our pipeline forward through initiation of enrollment in the ORCA-3 and ORCA-V1 trials in 2022.”
Achieve’s second cytisinicline Phase 3 registrational clinical trial, ORCA-3, is expected to initiate enrollment of approximately 750 adult cigarette smokers in the first quarter of 2022. The grant-funded Phase 2 ORCA-V1 study, investigating the efficacy of cytisinicline in approximately 150 adult nicotine e-cigarette users, is expected to initiate by the end of the second quarter of 2022, dependent on grant funding timelines.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.1,2 More than
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve, visit www.achievelifesciences.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time to time, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.
References
1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
FAQ
What are the ORCA-2 trial results for ACHV expected?
How many subjects were enrolled in the ORCA-2 trial?
What is the focus of Achieve Life Sciences' ORCA Program?
When will the ORCA-3 trial begin for ACHV?
What does cytisinicline aim to achieve?
